Omega Therapeutics reports FY 2023 net loss $97.4M; cuts headcount 35%, extends cash runway to Q1 2025

Omega Therapeutics, Inc.

Cash, equivalents and marketable securities $73.4M as of Dec. 31, 2023; expected to fund operations into Q1 2025.
OTX-2002 in HCC showed 80% disease control rate (4/5) in early cohorts; Cohort 5 (0.3 mg/kg) opened in March 2024.
Novo Nordisk collaboration for obesity: up to $532M in milestones plus tiered royalties; target enhances thermogenesis.
R&D expense $77.2M in 2023 vs $81.2M in 2022; net loss $97.4M vs $102.7M; headcount reduced ~35%.
Prioritized programs: OTX-2101 (NSCLC), HNF4A (liver regeneration), obesity controller; expect next clinical data mid-2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Omega Therapeutics, Inc. reported financial results for for the fourth quarter and full year ended December 31, 2023.

Period: for the fourth quarter and full year ended December 31, 2023
Result: reported results

Exact text from the filing

Omega Therapeutics, Inc. (the “Company”) issued a press release announcing financial results for the quarter and year ended December 31, 2023.

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0000950170-24-038053

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.